首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1290432

全球阿滋海默症藥物市場 - 2023-2030年

Global Alzheimer Drugs Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球阿滋海默症藥物市場在2022年達到39.7億美元，預計到2030年將見證有利可圖的成長，達到77億美元。在2023-2030年的預測期內，全球阿滋海默症藥物市場預計將呈現8.7%的複合年成長率。

全球阿滋海默症藥物市場正在擴大，原因包括慢性疾病（包括失智症）的發病率不斷增加，治療管道的規模不斷擴大，用於診斷和藥物開發的生物標記的支出，以及為早期檢測創造更複雜的診斷方法。

阿爾茨海默症藥物市場的藥物類型範圍包括阿爾茨海默症藥物，如多奈哌齊、加蘭他明、里瓦斯蒂明、美滿黴素和其他，這增加了阿爾茨海默症藥物類型的市場佔有率。這些藥物可以減輕或調節一些行為和認知問題。阿滋海默症藥物的發展和各國即將進行的醫療審批也為市場成長創造了積極的前景。

市場動態

在藥物開發中使用生物標記和大型管道推動了阿滋海默症藥物市場的成長。

創造藥物的風險很高，而生物標記是降低風險和提高技術成功率的實用手段。對阿爾茨海默症的理解正在迅速發展，重要的生物事件現在正在被確認。通過大腦成像、血液或腦脊液（CSF）中可以看到的生物標記可能偶爾會伴隨這些事件的發生。

通過利用這些生物標記來改善藥物開發過程，有可能減少與阿滋海默症療法的產生有關的風險。因此，生物標記在開發阿滋海默症療法中的意義越來越大，從而推動了阿滋海默症藥物市場的發展。

不斷成長的研究和開發以及阿爾茨海默症患病率的上升為製造商創造了有利可圖的機會。

由於主要參與者在研究和開發能力方面進行了大量投資，以實現尖端技術的改進，因此存在著一個發展中的市場機會。影響市場的另一個趨勢是對阿滋海默症治療的需求不斷成長。根據《世界阿滋海默症報告》，目前有5000萬阿滋海默症或相關失智症患者，到2050年，這個數位預計將上升到1.52億。

此外，美國食品和藥物管理局已經授權使用兩類藥物，即膽鹼酯酶抑製劑（Aricept, Exelon, Razadyne）和美滿黴素（Namenda），來治療阿滋海默症的認知副作用，如記憶喪失、迷失方向以及思考和推理問題。隨著更多診斷和治療阿滋海默症的臨床試驗的進行，市場將因此而上升。

晚期藥物的高失敗率將阻礙市場的成長

然而，由於高級藥物的價格令人望而卻步，後期階段的探索性候選藥物無能為力，以及貧窮國家對阿滋海默症的認知水平不高，全球阿滋海默症藥物市場在預測期內可能受到阻礙。

例如，20222年11月，羅氏集團旗下的基因泰克公司發布了調查甘特納魯單抗用於阿滋海默症和輕度阿滋海默症失智症（一般稱為早期阿滋海默症）促使的輕度認知障礙（MCI）患者的GRADUATE I和II III期研究的結果。該研究的主要目標是減少臨床衰退，但沒有實現。

COVID-19影響分析

COVID-19分析包括COVID前情景、COVID情景和COVID後情景，此外還有定價動態（包括大流行期間和之後的定價變化，與COVID前情景進行評估）、需求-供應譜（由於貿易限制、封鎖和之後的問題促使的需求和供應轉移）、政府計劃（政府機構重新激活市場、產業或部門的計劃）和製造商戰略計劃。

俄烏戰爭影響分析

由於該地區的主要市場參與者數量較少，估計俄烏衝突對全球阿滋海默症藥物市場的影響不大。然而，在預測期內，原料進出口的影響預計對全球阿滋海默症藥物市場的成長影響不大。

Market Overview

The Global Alzheimer Drugs Market reached US$ 3.97 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 7.7 billion by 2030. The global alzheimer drugs market is expected to exhibit a CAGR of 8.7% during the forecast period 2023-2030.

The global market for Alzheimer's medications is expanding due to factors including the increasing prevalence of chronic diseases, including dementia, the growing size of the therapeutic pipeline, expenditures in biomarkers for diagnosis and drug development, and the creation of more sophisticated diagnostics for early detection.

The Alzheimer drugs market's drug type scope comprises Alzheimer drugs like donepezil, galantamine, rivastigmine, memantine and others, which has increased the market share for Alzheimer drugs type. These medications could lessen or regulate some behavioral and cognitive issues. Alzheimer's drugs developments and upcoming medical approvals across countries are also creating a positive outlook for market growth.

Market Dynamics

Use of Biomarkers in Drug Development and Large Pipeline Drive the Growth of the Alzheimer Drugs Market.

The risk involved in creating medication is high, and biomarkers present a practical means of reducing the risk and enhancing technical success. The understanding of Alzheimer is rapidly developing, and important biological events are now being identified. Biomarkers that can be seen by brain imaging, in the blood or in the cerebrospinal fluid (CSF) may occasionally accompany these occurrences.

By utilizing these biomarkers to improve the drug development process, it may be possible to reduce the risk associated with the creation of Alzheimer therapies. As a result, the market for Alzheimer's pharmaceuticals is being driven by the increasing significance of biomarkers in developing AD therapies.

Growing Research and Development and Rising Prevalence of Alzheimer Creates Lucrative Opportunities for Manufacturers.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Another trend influencing the market is the growing demand for Alzheimer treatment. According to the World Alzheimer Report, there are currently 50 million people living with Alzheimer's disease or related dementia, and by 2050, that number is expected to rise to 152 million.

Additionally, the FDA has authorized the use of two pharmacological classes, cholinesterase inhibitors (Aricept, Exelon, Razadyne), and memantine (Namenda), to treat the cognitive side effects of Alzheimer's disease, such as memory loss, disorientation, and problems with thinking and reasoning. With more clinical trials being conducted for the diagnosis and treatment of Alzheimer's, the market will rise as a result.

High failure Rates of Late-Stage Drugs will Hamper the Growth of the Market

The global marketplace for Alzheimer's drugs, however, may be constrained over the projected period due to the prohibitive prices of advanced medications, the inability of exploratory candidates during the latter stages, and the low level of knowledge of Alzheimer's disease in poor countries.

For instance, in November 20222, results from the GRADUATE I and II Phase III studies investigating gantenerumab in patients with mild cognitive impairment (MCI) owing to Alzheimer's and mild Alzheimer's dementia, generally known as early Alzheimer's disease, were released by Genentech, a member of the Roche Group. The research' main goal of decreasing clinical decline was not achieved.

COVID-19 Impact Analysis

The COVID-19 Analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics (Including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply due to trading restrictions, lockdown, and afterward issues), Government Initiatives (Initiatives to reactivate a market, industry, or sector by Government Bodies), and Manufacturers Strategic Initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global alzheimer drugs market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global alzheimer drugs market growth over the forecast period.

Segment Analysis

The Global Alzheimer Drugs Market is segmented based on drug type, distribution channel and region.

Hospital Pharmacy from the Distribution Channel Segment Accounts for 40.1% of Market Share. Owing to Rising Hospital Admissions

The goal of hospital pharmacy is to constantly maintain and improve patient medication administration to the greatest levels imaginable. Controlling the usage of pharmaceuticals in hospitals and other medical facilities is the main responsibility of hospital pharmacies. One of the goals is to enhance patient outcomes through the prescription, procurement, distribution, management, and review of medications.

Hospital pharmacies will see an increase in demand thanks to benefits including teaching patients how to take their prescriptions, giving them in an emergency, and aiding with specialized medical treatment, like for cancer patients.

If necessary, the hospital pharmacy can assist with modifying dosages or altering drugs. Finding medicine formulations that the patient can use (such as injections, suppositories, and nasal sprays), and making sure the container can be read and opened with ease. identifying potential health issues unrelated to dementia. Hence above-mentioned factors prove that hospital pharmacies will be the largest market shareholder.

Geographical Analysis

North America accounted for approximately 39.2% of the market share due to major players' strong presence and increasing technological advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for Alzheimer drugs for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of Alzheimer drugs, increasing demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand of Alzheimer drugs applications. Rising new product launches for using in patients with dementia or Alzheimer will drive the market growth.

Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for Alzheimer such as biomarkers, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the alzheimer drugs market include: F. Hoffmann-La Roche, Merck & Co., Novartis AG, Pfizer Inc., Eli Lily and Co., Biogen Inc., Johnson & Johnson, AbbVie, Siemens Healthineers and Lupin among others.

Why Purchase the Report?

To visualize the Global Alzheimer Drugs Market segmentation based on drugs type, distribution channel and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Alzheimer drugs market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Alzheimer Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Drugs Type
3.2. Snippet by Distribution Channel
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Use of biomarkers in drug development and large pipeline
  - 4.1.1.2. Large number of drugs in pipeline
- 4.1.2. Restraints
  - 4.1.2.1. High failure rates of late-stage drugs
- 4.1.3. Opportunity
  - 4.1.3.1. Growing research and development and rising prevalance of Alzheimer
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Drugs Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 7.1.2. Market Attractiveness Index, By Drugs Type
7.2. Donepezil *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Galantamine
7.4. Rivastigmine
7.5. Memantine
7.6. Others

8. By Distribution Channel

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. The U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. The U.K.
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan

Australia

9.5.5.4. Rest of Asia-Pacific

9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. F. Hoffmann-La Roche *
- 11.1.1. Company Overview
- 11.1.2. Drugs Type Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Novartis AG
11.3. Merck & Co.
11.4. Pfizer Inc.
11.5. Eli Lily and Co.
11.6. Biogen Inc.
11.7. Johnson & Johnson
11.8. Lupin
11.9. AbbVie Inc.
11.10. Siemens Healthineers

LIST NOT EXHAUSTIVE